Lack of TIR8/SIGIRR triggers progression of chronic lymphocytic leukemia in mouse models

Blood

Volumn 118, Issue 3, 2011, Pages 660-669

  Bertilaccio, Maria Teresa Sabrina ^a   Simonetti, Giorgia ^a,b   Dagklis, Antonis ^a   Rocchi, Martina ^a   Rodriguez, Tania Veliz ^a   Apollonio, Benedetta ^a,c   Mantovani, Alberto ^d   Ponzoni, Maurilio ^a   Ghia, Paolo ^a,d   Garlanda, Cecilia ^c,d   Caligaris Cappio, Federico ^a,c,d   Muzio, Marta ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^d IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CD5 ANTIGEN; INTERLEUKIN 1 RECEPTOR; MEMBRANE RECEPTOR; MESSENGER RNA; TOLL LIKE RECEPTOR; TRANSMEMBRANE INHIBITORY RECEPTOR 8; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; CANCER GROWTH; CELL EXPANSION; CELL TRANSFORMATION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; FLOW CYTOMETRY; GENE REARRANGEMENT; IMMUNOHISTOCHEMISTRY; LEUKEMOGENESIS; LIFESPAN; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROLYMPHOCYTE; PROTEIN EXPRESSION; TRANSGENIC MOUSE;

EID: 79960691639     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-01-329870     Document Type: Article

References (44)

1. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008; 454(7203):436-444.
2. Muzio M, Bertilaccio MT, Simonetti G, Frenquelli M, Caligaris-Cappio F. The role of Toll-like receptors in chronic B cell malignancies. Leuk Lymphoma. 2009;50(10):1573-1580.
3. Muzio M, Mantovani A. Toll-like receptors (TLRs) signalling and expression pattern. J Endotoxin Res. 2001;7(4):297-300. (Pubitemid 33041068)
4. Akira S. TLR signaling. Curr Top Microbiol Immunol. 2006;3111-3116.
5. Muzio M, Mantovani A. The Toll receptor family. Allergy. 2001;56(2):103-108. (Pubitemid 32115759)
6. Lanzavecchia A, Sallusto F. Toll-like receptors and innate immunity in B-cell activation and antibody responses. Curr Opin Immunol. 2007;19(3):268-274. (Pubitemid 46687008)
7. Bourke E, Bosisio D, Golay J, Polentarutti N, Mantovani A. The toll-like receptor repertoire of human B lymphocytes: inducible and selective expression of TLR9 and TLR10 in normal and transformed cells. Blood. 2003;102(3):956-963. (Pubitemid 36917790)
8. Bernasconi NL, Onai N, Lanzavecchia A. A role for Toll-like receptors in acquired immunity: upregulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Blood. 2003;101(11):4500-4504. (Pubitemid 36857820)
9. Ruprecht CR, Lanzavecchia A. Toll-like receptor stimulation as a third signal required for activation of human naive B cells. Eur J Immunol. 2006;36(4):810-816.
10. Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature. 2002;416(6881):603-607. (Pubitemid 34406754)
11. Lau CM, Broughton C, Tabor AS, et al. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J Exp Med. 2005;202(9):1171-1177. (Pubitemid 41586947)
12. Garlanda C, Riva F, Polentarutti N, et al. Intestinal inflammation in mice deficient in Tir8, an inhibitory member of the IL-1 receptor family. Proc Natl Acad Sci U S A. 2004;101(10):3522-3526. (Pubitemid 38338228)
13. Wald D, Qin J, Zhao Z, et al. SIGIRR, a negative regulator of Toll-like receptor-interleukin 1 receptor signaling. Nat Immunol. 2003;4(9):920-927. (Pubitemid 37098664)
14. Garlanda C, Anders HJ, Mantovani A. TIR8/SIGIRR: an IL-1R/TLR family member with regulatory functions in inflammation and T cell polarization. Trends Immunol. 2009;30(9):439-446.
15. Garlanda C, Riva F, Veliz T, et al. Increased susceptibility to colitis-associated cancer of mice lacking TIR8, an inhibitory member of the interleukin-1 receptor family. Cancer Res. 2007;67(13):6017-6021. (Pubitemid 47037479)
16. Xiao H, Gulen MF, Qin J, et al. The Toll-interleukin-1 receptor member SIGIRR regulates colonic epithelial homeostasis, inflammation, and tumorigenesis. Immunity. 2007;26(4):461-475. (Pubitemid 46602997)
17. Xiao H, Yin W, Khan MA, et al. Loss of single immunoglobulin interlukin-1 receptor-related molecule leads to enhanced colonic polyposis in Apc-(min) mice. Gastroenterology;139(2):574-585.
18. Caligaris-Cappio F, Ghia P. Novel insights in chronic lymphocytic leukemia: are we getting closer to understanding the pathogenesis of the disease? J Clin Oncol. 2008;26(27):4497-4503.
19. Ghia P, Scielzo C, Frenquelli M, Muzio M, Caligaris-Cappio F. From normal to clonal B cells: Chronic lymphocytic leukemia (CLL) at the crossroad between neoplasia and autoimmunity. Autoimmun Rev. 2007;7(2):127-131. (Pubitemid 350116725)
20. Dungarwalla M, Matutes E, Dearden CE. Prolymphocytic leukaemia of B- and T-cell subtype: a state-of-the-art paper. Eur J Haematol. 2008;80(6):469-476. (Pubitemid 351677465)
21. Catovsky D. Prolymphocytic leukaemia. Nouv Rev Fr Hematol. 1982;24(6):343-347. (Pubitemid 13220829)
22. Bichi R, Shinton SA, Martin ES, et al. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci U SA. 2002;99(10):6955-6960. (Pubitemid 34526239)
23. Yan XJ, Albesiano E, Zanesi N, et al. B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2006;103(31):11713-11718. (Pubitemid 44182516)
24. Muzio M, Scielzo C, Bertilaccio MT, Frenquelli M, Ghia P, Caligaris-Cappio F. Expression and function of toll like receptors in chronic lymphocytic leukaemia cells. Br J Haematol. 2009;144(4):507-516.
25. Anderson LA, Landgren O, Engels EA. Common community acquired infections and subsequent risk of chronic lymphocytic leukaemia. Br J Haematol. 2009;147(4):444-449.
26. Landgren O, Rapkin JS, Caporaso NE, et al. Respiratory tract infections and subsequent risk of chronic lymphocytic leukemia. Blood. 2007;109(5):2198- 2201. (Pubitemid 46348222)
27. Scielzo C, Bertilaccio MT, Simonetti G, et al. HS1 has a central role in the trafficking and homing of leukemic B cells. Blood;116(18):3537-3546.
28. Polentarutti N, Rol GP, Muzio M, et al. Unique pattern of expression and inhibition of IL-1 signaling by the IL-1 receptor family member TIR8/SIGIRR. Eur Cytokine Netw. 2003;14(4):211-218. (Pubitemid 38122227)
29. Frenquelli M, Muzio M, Scielzo C, et al. MicroRNA and proliferation control in chronic lymphocytic leukemia: functional relationship between miR-221/222 cluster and p27. Blood; 115(19):3949-3959.
30. Dalloul A. CD5: a safeguard against autoimmunity and a shield for cancer cells. Autoimmun Rev. 2009;8(4):349-353.
31. Caligaris-Cappio F, Riva M, Tesio L, Schena M, Gaidano G, Bergui L. Human normal CD5+ B lymphocytes can be induced to differentiate to CD5- B lymphocytes with germinal center cell features. Blood. 1989;73(5):1259-1263. (Pubitemid 19107431)
32. Takeuchi H, Katayama I. Interleukin 1 (IL-1 alpha and IL-1 beta) induces differentiation/activation of B cell chronic lymphoid leukemia cells. Cytokine. 1994;6(3):243-246. (Pubitemid 24263865)
33. Defrance T, Vanbervliet B, Durand I, Banchereau J. Human interleukin 4 down-regulates the surface expression of CD5 on normal and leukemic B cells. Eur J Immunol. 1989;19(2):293-299. (Pubitemid 19098905)
34. Garaud S, Le Dantec C, Jousse-Joulin S, et al. IL-6 modulates CD5 expression in B cells from patients with lupus by regulating DNA methylation. J Immunol. 2009;182(9):5623-5632.
35. Nakamura M, Burastero SE, Notkins AL, Casal P. Human monoclonal rheumatoid factor-like antibodies from CD5 (Leu-1)+ B cells are polyreactive. J Immunol. 1988;140(12):4180-4186.
36. Xu H, Liew LN, Kuo IC, Huang CH, Goh DL, Chua KY. The modulatory effects of lipopolysaccharide-stimulated B cells on differential T-cell polarization. Immunology. 2008;125(2):218-228.
37. Huang B, Zhao J, Shen S, et al. Listeria monocytogenes promotes tumor growth via tumor cell toll-like receptor 2 signaling. Cancer Res. 2007;67(9):4346-4352. (Pubitemid 46815083)
38. Mittal D, Saccheri F, Venereau E, Pusterla T, Bianchi ME, Rescigno M. TLR4-mediated skin carcinogenesis is dependent on immune and radio-resistant cells. EMBO J.;29(13):2242-2252.
39. Salaun B, Coste I, Rissoan MC, Lebecque SJ, Renno T. TLR3 can directly trigger apoptosis in human cancer cells. J Immunol. 2006;176(8):4894-4901.
40. Liang X, Moseman EA, Farrar MA, et al. Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells. Blood. 2010;115(24):5041-5052.
41. Cherfils-Vicini J, Platonova S, Gillard M, et al. Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance. J Clin Invest. 2010;120(4):1285-1297.
42. Kanzler H, Barrat FJ, Hessel EM, Coffman RL. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med. 2007;13(5):552-559. (Pubitemid 46830615)
43. Rakoff-Nahoum S, Medzhitov R. Toll-like receptors and cancer. Nat Rev Cancer. 2009;9(1):57-63.
44. Tarnani M, Laurenti L, Longo PG, et al. The proliferative response to CpG-ODN stimulation predicts PFS, TTT and OS in patients with chronic lymphocytic leukemia. Leuk Res. 2010;34(9):1189-1194.